Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through the company's transformative plans for 2025, emphasizing significant milestones and clinical developments.
Reflecting on 2024, Vitt highlighted progress in the ENSURE-1 and ENSURE-2 Phase 3 studies for relapsing multiple sclerosis (MS), which are on track for completion in 2026. A key achievement of the year was a successful interim analysis, which maintained the study's integrity without adjustments.
On the corporate front, Immunic secured a PIPE investment of up to $240 million, providing a cash runway into Q3 2025 based on the additional $80 million tranche. Vitt said the company also welcomed Jason Tardio as chief operating officer, whose extensive experience in MS commercialization will be pivotal as Immunic prepares for potential product launches.
Looking ahead, April 2025 will bring the clinical readout of the CALLIPER study for progressive MS. Vitt believes vidofludimus calcium has the potential to become the first holistic oral treatment for all forms of MS, a breakthrough based on promising Phase 2 and biomarker data.